国产又大又粗又长,美女在线视频亚洲蜜桃,一区二区不卡的黄色,日韩精品码人妻,大鸡巴操逼国产视频,人妻系列在线播放,亚洲特色黄大片,亚洲AV四区,夜夜操综合

阻塞性睡眠呼吸暫停（簡稱OSA），在美國影響數(shù)百萬人和其他國家更多的人。幸運的是，在非手術(shù)治療中，存在一個有效的持續(xù)氣道正壓通氣裝置（簡稱CPAP），可用在患者睡覺時。不幸的是，通過改進(jìn)設(shè)備和教育患者的努力，患有OSA的患者使用 CPAP仍然在40-50%的范圍。 我們尋求增加和堅持使用CPAP治療OSA的創(chuàng)新解決方案。提交的解決方案可以采取各種各樣的方法來解決的患者在心理上，身體上，或不適應(yīng)CPAP等問題。 提交方案請在：https://www.innocentive.com/ar/challenge/9933907　上投稿。 截止日期：2016年9月21日

確定性生物標(biāo)記物用來預(yù)測癲癇猝死，具有巨大的醫(yī)療前景。雖然有幾個假設(shè)猝死的原因，癲癇患者的死亡率和如何防止它仍然是一個謎。新的研究表明，癲癇發(fā)作后，抑制大腦活動、損害呼吸和心臟功能等生理變化最終導(dǎo)致癲癇猝死。另外，在一次或多次驚厥后的一小時內(nèi)通常發(fā)生癲癇猝死。 目前很少有干預(yù)措施，可以預(yù)測和預(yù)防癲癇患者的癲癇猝死。因此，針對癲癇猝死高?；颊撸d癇病基金會要求，對其特殊敏感性生物標(biāo)記物進(jìn)行臨床研發(fā)，生物標(biāo)記物可以是基因?qū)用?、結(jié)構(gòu)層面、代謝層面，生理層面或其他形式，理想的生物標(biāo)記物或生物標(biāo)記物組會被很容易地，安全地測量，具有成本效益的，可以檢測，修改與介入，并始終與癲癇猝死或接近癲癇猝死相關(guān)聯(lián)，這樣的生物標(biāo)記物（生物標(biāo)記物組）有利于高危癲癇患者的預(yù)防和治療。 項目1， 詳細(xì)解釋項目的計劃方法，材料，人員，資源，進(jìn)度，能生成數(shù)據(jù)，并有潛在的能力完成項目2和項目3。截止日期2016年10月10日下午11:59（美國東部時間）。 項目2，按照投資方的指示，中標(biāo)方需要提交在體內(nèi)、體外的數(shù)據(jù)和測試證明。截止日期2017年10月10日下午11:59（美國東部時間）。 項目3， 中標(biāo)方必須記錄他們的進(jìn)展與季度報告。在體內(nèi)的生物標(biāo)記物的預(yù)測最終的驗證數(shù)據(jù)。截止日期2020年10月10日下午11:59（美國東部時間）。 投標(biāo)截止日期：2016年10月10日 投標(biāo)地址：https://www.innocentive.com/ar/challenge/9933784

抗體的引用，使藥物的靶點進(jìn)一步擴大治療范圍，改善了患者的預(yù)后效果。Boehringer Ingelheim公司試圖尋找其他方法，它具有高電位治療或調(diào)節(jié)人類疾病的治療方法。這些模式應(yīng)該在初始狀態(tài)下展示哺乳動物細(xì)胞體外或體內(nèi)的價值。 Boehringer Ingelheim公司會在投稿中選擇一個合作伙伴，同時會獎勵3個“質(zhì)量”最高的稿件3000美金。 懸賞截止時間為2016年9月25日下午11:59止（美國東部時間）。 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/challenge/9933874

痤瘡(粉刺)是一種慢性炎癥性皮膚病，通常開始于青春期，其特點是在臉上的青春痘，也會出現(xiàn)在頸部和身體上。發(fā)作的痤瘡?fù)梢猿晒Φ赝ㄟ^藥物治療和完善的日常護(hù)理方案調(diào)整皮膚類型。輕度和中低度痤瘡用局部治療方法，而中度至重度痤瘡患者需要口服治療?；颊呖赡軙龅讲槐匾母弊饔?，如皮膚刺激，甚至抗生素耐藥性。未得到治療的瘢點或控制不佳會導(dǎo)致永久性的疤痕、情感上的痛苦，心理焦慮和抑郁等問題。痤瘡的醫(yī)療需求仍然未滿足，特別是對那些不對應(yīng)標(biāo)準(zhǔn)的護(hù)理療法的人。因此尋找新的治療方法，以改善痤瘡患者的生活。 懸賞截止時間為2016年8月31日下午11:59止（美國東部時間）。 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/challenge/9933873?challenge=9933873

通常情況下，清潔假牙污漬，給假牙消毒是一系列費力又乏味的過程，如：取下假牙，用水沖洗，準(zhǔn)備清潔劑，把假牙浸泡在清潔劑中，洗刷假牙，等等。 尋求一種高效清潔技術(shù)，能簡化上述中一些復(fù)雜的過程，從而達(dá)到更高效的用戶體驗。如：把假牙放到清潔劑中，直接達(dá)到清潔的作用。 懸賞截止日期：2016年6月19日 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/challenge/9933825 原文： Challenge Overview Maintaining dentures clean, free from stains and disinfected, requires a number of laborious and tedious procedures when they are out of the mouth. Removing the denture, rinsing the denture, preparing a cleaning solution, soaking and brushing the denture, are all tasks that have to be repeatedly performed and that consumers find cumbersome. A great improvement for consumer experience would be to have a highly efficient cleanser that would make denture care easier. Imagine for example a situation where it would be as simple as removing the denture and immersing it for a few seconds in a liquid solution – this would be a dream scenario. Therefore, the Seeker is seeking for novel alternative cleanser technologies that are be more consumer-friendly but still highly efficient. This is a Theoretical Challenge that requires only a written proposal to be submitted. The Challenge award will be contingent upon theoretical evaluation of the proposal by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution. However, the Seeker will be willing to consider a licensing agreement for a partial award if exclusive IP cannot be transferred by the Solver. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 19, 2016. Late submissions may not be considered. IMPORTANT NOTE: The Seeker for this Challenge requires additional Solver verification and due diligence. Please read carefully the respective sections in the Challenge Specific Agreement for further information or use your Project Room to ask a question.

為進(jìn)一步加強食品藥品安全宣傳教育，廣泛普及飲食用藥安全常識，全面提升社會公眾食品藥品安全知識水平，大力營造全社會共同關(guān)注、共同參與食品藥品安全工作的良好氛圍，省食品藥品監(jiān)督管理局即日起舉辦“吉林省首屆食品藥品科普創(chuàng)意大賽”，面向全社會征集食品藥品科普創(chuàng)意作品。具體方案如下： 一、活動主題 食美藥安，健康相伴 二、活動時間 2016年5月12日-2016年6月30日 三、組織機構(gòu) 主辦單位：吉林省食品藥品監(jiān)督管理局 承辦單位：吉林省鳳凰智業(yè)影視有限公司 媒體支持：吉林日報、吉林電視臺、吉林人民廣播電臺、新文化報、城市晚報、東亞經(jīng)貿(mào)新聞、手機報、新華網(wǎng)等。 四、 作品要求 （一） 作品主題 1、宣傳食品、藥品、保健食品、化妝品和醫(yī)療器械（“四品一械”）方面的法律法規(guī)和標(biāo)準(zhǔn)制度； 2、普及飲食用藥安全常識，倡導(dǎo)科學(xué)理性健康消費觀念； 3、宣揚“尚德守法”理念，增強食品藥品生產(chǎn)經(jīng)營者誠信守法的責(zé)任意識； 4、傳播食品藥品安全社會共治理念，鼓勵社會各界通過12331舉報食品藥品違法違規(guī)行為，同心攜手維護(hù)食品藥品安全。 （二）作品類型 1、平面設(shè)計類 格式：.TIFF、.JPG 分辨率：500dpi 尺寸：210MM（寬）X297MM（高） 色彩模式：RGB 大?。簡蝹€文件不大于5MB 2、視頻類 格式：不限形式，視頻拍攝、FLASH、動畫制作均可。 時長：30秒以上，2分鐘以內(nèi)。 分辨率：標(biāo)清視頻為720*576；高清視頻為1920*1080。 大?。簡蝹€文件不大于100MB （三）內(nèi)容要求 1、參與者可選擇一個或多個食品藥品安全主題進(jìn)行創(chuàng)作，要求作品形象生動、通俗易懂、積極健康，具有一定科普功能。 2、參賽作品應(yīng)觀點正確，符合國家法律、法規(guī)、規(guī)章和社會道德規(guī)范，體現(xiàn)公共利益。 3、參賽作品要求原創(chuàng)，凡涉及抄襲、模仿等問題的作品不得參賽。作品的著作權(quán)、與作品相關(guān)的肖像權(quán)、名譽權(quán)等法律問題，由參賽者自行解決并承擔(dān)責(zé)任。 五、參賽方式 （一）參賽報名 為及時掌握參賽情況，設(shè)置報名環(huán)節(jié)。登陸省局門戶網(wǎng)站，進(jìn)入大賽報名頁，網(wǎng)上報名。 （二）作品報送 填寫《參賽作品登記表》連同參賽作品一并發(fā)送至指定郵箱。在郵件主題上標(biāo)注“科普創(chuàng)意大賽-類別-姓名”，如：視覺創(chuàng)意大賽-平面設(shè)計類-張三。 參賽作品不予退還，參賽者自留底稿。 六、獎項設(shè)置 平面設(shè)計類、視頻類分別設(shè)置一、二、三等獎和優(yōu)秀作品獎。 七、步驟安排 （一）前期推介 以30秒短視頻及文字或圖片形式在新聞媒體上對活動進(jìn)行宣傳，同時在《吉林食品藥品安全報》、吉林省食品藥品監(jiān)督管理局門戶網(wǎng)站網(wǎng)及微信公眾平臺推介。 （二）作品征集 收集整理參賽作品，并在門戶網(wǎng)站展示。 （三）作品遴選 省局組織專家，圍繞作品主題，按照公平、公正、公開的原則，對所有參賽作品進(jìn)行審核，遴選出優(yōu)秀作品。遴選標(biāo)準(zhǔn)： 1、創(chuàng)意精巧，主題鮮明； 2、時效性強，突出正能量； 3、具有視覺沖擊力，適宜傳播。 （四）結(jié)果公布 活動結(jié)束后，在省食品藥品監(jiān)督管理局網(wǎng)站和微信平臺上公布獲獎作品名單。 本次活動對征集作品具有合法使用權(quán)，作品將在指定媒體、網(wǎng)站及相關(guān)活動中公開展播或刊登，不另付稿酬。

從成本效益角度出發(fā)，尋找一種可以大規(guī)模生產(chǎn)天然葉醇的制造技術(shù)。需要提供出參考資料，實驗數(shù)據(jù)和樣品。參考資料中需要列出技術(shù)需求，詳細(xì)描述的實驗數(shù)據(jù)，同時需要提供原材料的樣品。 轉(zhuǎn)讓知識產(chǎn)權(quán)后，將收到賞金。 懸賞截止日期：2016年8月18日 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/projectRoom/index?challenge=9933857 Challenge Overview Cis-3-hexenol (leaf alcohol) is a fragrant compound naturally produced by plants. Its characteristic odor has made it a highly successful natural green compound in the flavor and fragrance industry. High demand for this ingredient makes it a constant challenge for the industry to develop processes that can, at a low production cost per kg, allow for the consistent, sustainable and high-quality manufacturing of multi tones of this product. Hence, the Seeker is challenging scientists and technologists to come up with whole processes (from production to downstream processing) to meet this need. Please read the Detailed Description section to learn about the technical requirements that your proposed process should meet. The submission to the Challenge should include the following: 1. The detailed description of the proposed Solution addressing specific Technical Requirements presented in the Detailed Description of the Challenge. This description should be accompanied by a well-articulated rationale supported by literature/patent precedents. 2. Experimental data obtained as outlined in the Detailed Description of the Challenge (and/or delivery of a material sample of the product if requested by the Seeker). The Challenge award is contingent upon theoretical evaluation and experimental validation on a 15 L pilot scale of the submitted Solutions by the Seeker. To receive an award, the Solvers will have to transfer to the Seeker their exclusive Intellectual Property (IP) rights to the solution. Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on August 18, 2016. Late submissions will not be considered.

控制體內(nèi)血糖水平是成功治療許多疾病的關(guān)鍵，如糖尿病。 因此， Novo Nordisk公司正在尋找新的小分子，它可以于D-葡萄糖的生理集合密切結(jié)合 (持續(xù)的取代，Kd，低毫摩爾范圍) 懸賞須提交概念性實驗數(shù)據(jù)報告和樣品，Novo Nordisk公司將決定最終得獎?wù)?，并頒發(fā)起始獎金200000美金。 另外Novo Nordisk公司將提議基于里程碑式的合約，如果分子式在未來懸賞中得到成功研發(fā)，將會得到二次獎項。 懸賞截止時期2017年1月9日, 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/projectRoom/index?challenge=9933823 原文: Novo Nordisk Challenge: Design and Synthesis of a Small Molecule Glucose Binder TAGS: Chemistry, Life Sciences, Royal Society of Chemistry, RTP AWARD: $200,000 USD | DEADLINE: 1/09/17 | ACTIVE SOLVERS: 145 | POSTED: 3/30/16 The control of glucose levels in the body is key for successful treatment of many disease states such as diabetes. Hence, Novo Nordisk is looking for novel small molecules that can bind with affinities matching the physiological concentrations of D-glucose (displacement constant, Kd, in the low millimolar range). This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and sample delivery. Additionally, the Challenge has the following unique features.Please read carefully the Challenge-Specific Agreement. ? Solvers are asked to prepare the compound and perform binding affinity assays to glucose in aqueous solution under conditions described in the Challenge Description. The compounds must also be supplied to Novo Nordisk in sufficient amounts to reproduce the results. Upon experimental validation of the results, Novo Nordisk will make an award (‘Initial Transfer Fee’) of $200,000 to the best solution as solely determined by the Seeker, according to the Challenge requirements. The Awarded Solver grants Novo Nordisk an exclusive license under the terms described in the Challenge-Specific Agreement. ? Additionally, Novo Nordisk will offer a milestone-based agreement to the Solver, establishing the terms of payment of anadditional award (‘Secondary Award’), should the small molecule be successful in its development post-Challenge(‘Second Evaluation Period’), in exchange for the assignment of exclusive IP rights to the Seeker. Source: InnoCentive Challenge ID: 9933823 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive RTP Challenge-Specific Agreement Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Challenge only, as permitted in the Terms of Use. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. If you click \\\\\\\\"I agree\\\\\\\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\\\\\\\"CSA\\\\\\\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge and in addition to your agreement to abide by the Terms of Use when you registered as a Solver. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply. 1. Your Responsibility to Avoid Obstacles. InnoCentive needs to know that if you solve the InnoCentive Challenge there will not be any legal obstacles to completing the license or sale of your rights to InnoCentive and subsequently to Seeker, which is the only way that you can receive the Initial Transfer Fee or the Secondary Award. You agree to be responsible for avoiding any legal obstacles to transferring the Proposed Solution and the associated work product (altogether, the “Work Product”) as well as all related Intellectual Property (altogether, the \\\\\\\\"Solution IP\\\\\\\\") if you submit a Proposed Solution chosen as a winning Solution. You will not receive an Initial Transfer Fee or Secondary Award if you cannot transfer the Solution IP. 2. Your Guarantee. You agree that if and when the time comes to assign and transfer the Solution IP, you will give a guarantee (the \\\\\\\\"Guarantee\\\\\\\\") that the assignment and transfer is lawful in exchange for the one-time payment of the Initial Transfer Fee or the Secondary Award to you alone, and that no consents, approvals or contracts that you did not already have before starting the InnoCentive Challenge are necessary from or with anyone else, such as: a. Your employer; b. Any former employer or other entity you are or have been associated with or have a contract with regarding Intellectual Property you develop; c. Anyone collaborating with you on the development of the Solution IP; d. Anyone else whose Intellectual Property you use or incorporate in the Solution IP; e. Any government official, regulatory body or other authority (for example, if any of the Solution IP is within the scope of a technology export control law in your country prohibiting its transfer to InnoCentive in the United States, or if the required assignments or licenses of the Solution IP are otherwise subject to public registration, review and/or approval) f. The holder of any lien (for example, if a bank or other creditor has obtained a mortgage or security interest in any of the Solution IP); g. Anyone who may be entitled to royalties or other payments relating to any of the Solution IP either by law or contract. 3. Your Obligations to Protect Potential Solution IP. In order to be eligible for an Initial Transfer Fee or the Secondary Award, during the period from when you begin work on the InnoCentive Challenge until the expiration of the First Evaluation Period or the Second Evaluation Period, as applicable, as set forth in the Challenge Statement, you shall not: a. Grant away any rights in the Work Product, Intellectual Property or Proposed Solution you are developing (\\\\\\\\"Potential Solution IP\\\\\\\\"), or do anything else that would prevent you from granting the rights to Seeker in accordance with this CSA; b. Reveal to any third party, except on terms of strict confidentiality, any information that relates to Potential Solution IP or do anything else likely to impair any of the Potential Solution IP; or c. Do anything that would cause the failure of your Guarantee. 4. Exclusivity Period. By submitting your Proposed Solution you agree to grant to InnoCentive and the Seeker for a period of 60 days from the later of the deadline set forth in the InnoCentive Challenge Statement or Seeker’s receipt of a sample of the Proposed Solution (the \\\\\\\\"First Evaluation Period\\\\\\\\") an exclusive, worldwide license to use, copy, distribute and create derivative works of the Proposed Solution and Solution IP for purposes of review, analysis and testing the Proposed Solution. If Seeker within the First Evaluation Period notifies InnoCentive of any Proposed Solution that Seeker has determined shall be a winning Solution that will be awarded the Initial Transfer Fee, you further grant to InnoCentive and Seeker (i) an exclusive, fully-paid license to use, copy, distribute and create derivative works of the Proposed Solution and Solution IP for its internal testing and non-commercial use for a period of 12-36 months from payment of the Initial Transfer Fee (the “Second Evaluation Period”), and (ii) an exclusive option (the “Option”) to negotiate with the Solver in good faith to fully acquire any and all exclusive rights to the Proposed Solution and Solution IP by paying to you the Secondary Award (collectively, these exclusive rights and the option are referred to as the “Exclusive Rights”). The Second Evaluation Period will initially be 12 months, but Seeker shall have the option to extend the Second Evaluation Period twice, each time by additional 12 months, providing for a maximum period of 36 months. If Seeker decides to extend the Second Evaluation Period beyond the initial 12 months, Seeker will pay to Solver a one-time only “Secondary Evaluation Period Extension Fee” of [$20,000]. If Seeker decides not to use the Option and pay the Secondary Award, the “Secondary Evaluation Period Extension Fee” will not be refundable. If Seeker decides to use the Option and pays to Solver the Secondary Award, the option payment will be deducted from the Secondary Award. InnoCentive will make reasonable efforts to transmit relevant Proposed Solutions to Seeker, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution submitted in response to an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning Work Product and your Proposed Solution to InnoCentive or the Seeker during the First Evaluation Period and Second Evaluation Period, if requested. By granting the Exclusive Rights you agree that during the First Evaluation Period and Second Evaluation Period (and thereafter, if the Option is exercised), you are prohibited from (x) using, the Proposed Solution or the Solution IP or (y) disclosing to or granting or assigning or transferring any rights to a third party to use the Proposed Solution or the Solution IP for any purpose, including the application for patents or similar intellectual property rights. 5. Acceptance of Proposed Solution and Transfer of Intellectual Property. InnoCentive will notify you within a commercially reasonable period of time after the deadline set forth in the InnoCentive Challenge Statement and before the expiry of the First Evaluation Period whether a Seeker accepts your Proposed Solution and wishes to exercise its right to extend the evaluation process into the Second Evaluation Period (\\\\\\\\"Acceptance\\\\\\\\"). For purposes of this Agreement, \\\\\\\\"Acceptance\\\\\\\\" shall mean the selection of your Proposed Solution by the Seeker as meeting the Solution Acceptance Criteria as set forth in the InnoCentive Challenge Statement. The Seeker has absolute and sole discretion to determine whether to Accept your Proposed Solution, or any Proposed Solution, and whether to make an Initial Transfer Fee or the Secondary Award, multiple Initial Transfer Fee or the Secondary Awards or any Initial Transfer Fee or the Secondary Award. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver, if any. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver, if any. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\\\\\\\'s failure to win an award. The meeting of the Solution Acceptance Criteria does not mean that the Proposed Solution will be Accepted by a Seeker. In the event that your Proposed Solution is not Accepted within the First Evaluation Period, the Exclusive Rights will terminate without further notice to you. Upon Acceptance of your Proposed Solution by a Seeker and payment of a Secondary Award to you (see \\\\\\\\"Payments\\\\\\\\"), you hereby assign and convey to Seeker all rights, title, and interests in and to the Proposed Solution, the Solution IP and any Work Product that are related to the InnoCentive Challenge, and you retain no rights to the Proposed Solution, the Solution IP or the Work Product insofar as they are related to the InnoCentive Challenge. In the event that the Work Product cannot be assigned and conveyed under statutory law, you herewith grant to Seeker a worldwide, unlimited, perpetual, irrevocable, and exclusive license to use, make, have made, market, copy, modify, lease, sell, distribute, and create derivative works of the Work Product (all such rights collectively referred to as \\\\\\\\"Intellectual Property\\\\\\\\") . If you utilize any processes in development of the Work Product which are the subject of patent rights owned by you, you agree to grant to InnoCentive a worldwide, non-exclusive, perpetual, royalty-free right and license to practice any patented processes used in the Work Product, including the right to assign the foregoing license to Seekers. Furthermore, you agree that you will, during the term of this Agreement and at any time thereafter, execute all papers and do all things deemed necessary by InnoCentive or a Seeker to ensure that InnoCentive and the Seeker acquires all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, including the rights to all Intellectual Property embodied therein, and that ensures that all such rights are transferred to Seeker. Such cooperation and execution shall be performed without additional compensation to you; provided, however, InnoCentive shall reimburse you for reasonable out-of-pocket expenses incurred at the specific request of InnoCentive. Upon payment of the Secondary Award, or termination of the Exclusive Rights for any reason, there will be no further obligations between you and InnoCentive or the Seeker with respect to the Proposed Solution, the Work Product, or the InnoCentive Challenge, except for the limitations on use and disclosure described under \\\\\\\\"Confidentiality\\\\\\\\", below. 6. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an “Initial Transfer Fee” or a \\\\\\\\"Secondary Award\\\\\\\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of any of the awards, a \\\\\\\\"Revised Award Amount\\\\\\\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after occurrence of each of the following: 1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of award payment from the Seeker. Payment of any award is conditioned upon your cooperation with InnoCentive\\\\\\\'s verification procedures. The award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any award, or any part of any award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on awards shall be your sole responsibility. 7. Escrows. The transfers of Solution IP and the Initial Transfer Fee or Secondary Award or any Revised Award Amount (as determined by Seeker) will be in escrow as follows: a. Your transfer of the Solution IP will be to InnoCentive as escrow agent for the Seeker. The Solution IP will be released from this escrow and transferred to the Seeker upon the occurrence of (a) the completion of InnoCentive\\\\\\\'s verification of you; (b) the Seeker\\\\\\\'s payment of the Initial Transfer Fee or Secondary Award to InnoCentive; and (c) the Seeker\\\\\\\'s payment of any other fees of InnoCentive pursuant to the separate agreement between Seeker and InnoCentive. b. The Seeker\\\\\\\'s payment of the Initial Transfer Fee or Secondary Award will be to InnoCentive as escrow agent for you. The Initial Transfer Fee or Secondary Award will be released from this escrow and transferred to you as soon as payment is due to you. 8. Confidentiality. During the term of this Agreement and at all times thereafter, you shall not disclose to any third party nor use for any purpose other than for the performance of this Agreement, any Confidential Information (as defined below) without the express written consent of the owner of the Confidential Information. These confidentiality obligations shall not apply to Confidential Information which: (a) is in the public domain, or which was publicly known or available on the date you originally accepted this Agreement (\\\\\\\\"Effective Date\\\\\\\\"); or (b) after the Effective Date becomes available to the public in a manner not involving a breach of any duty under this Agreement. Nothing herein shall preclude the ultimate disclosure of any information required by law. \\\\\\\\"Confidential Information\\\\\\\\" includes: ? All information set forth in the password protected areas of the Service (\\\\\\\\"Service Information\\\\\\\\"), (the presentation of Service Information via the Service shall not be deemed to be a public disclosure for purposes of this Agreement and shall not operate as an exclusion from Confidential Information); and ? During the First Evaluation Period or Second Evaluation Period and after Acceptance and exercise of an Option relating to a InnoCentive Challenge, any Work Product, Solution IP or Proposed Solution relating to said InnoCentive Challenge. The same restrictions on disclosure and use of Confidential Information described in this Section shall apply to the use or disclosure by InnoCentive and Seekers of any Work Product, Solution IP or Proposed Solution during the Exclusivity Period and, if the Proposed Solution is not accepted, thereafter, unless the Proposed Solution, Solution IP or Work Product can be shown by business records of Seeker or InnoCentive to (1) have been known to them previously; (2) is independently created by personnel of Seeker or InnoCentive who had no access to the Proposed Solution, Solution IP or the Work Product; or (3) is subject to the exceptions to Confidentiality in (a) or (b) of this section; provided, however, notwithstanding the foregoing, nothing in this Solver Agreement shall prevent a Seeker from utilizing a winning Solution, for which a Secondary Award has been paid, to the extent that a winning Solution and any rejected Proposed Solution contain overlapping Work Product or Solution IP. 9. Notwithstanding anything herein to the contrary, you recognize that other persons may have provided Seeker or others, or made public, or may in the future submit, or make public, materials that are the same or similar to your Proposed Solution. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\\\\\\\'s use of such materials. 10. General Conditions: InnoCentive and/or Seeker has the right to verify each Solver\\\\\\\'s eligibility and compliance with this CSA, and to eliminate any Solver, or terminate any Solver\\\\\\\'s registration on the basis of its investigation. Participation is conditioned on providing the data required on the online registration form. Personal data will be processed in accordance with InnoCentive\\\\\\\'s Privacy Policy which can be located athttp://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. Seeker reserves the immediate right to disqualify any Solver who, in InnoCentive\\\\\\\'s sole discretion: (i) is not in compliance with the Terms of Use or this CSA, (ii) tampers with the submission process, the Challenge, or the Website; or (iii) is acting in an uncooperative, unsportsmanlike, disruptive, abusive, or threatening manner. 11. Third Party Beneficiary. You and InnoCentive acknowledge and agree that any Seeker shall be a third- party beneficiary of this Agreement, and each shall have the right to assert and enforce the provisions of this Agreement directly on its own behalf. 12. Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls.

Boehringer Ingelheim公司尋找一種有機小分子，能夠安全使用，沒有生物活性，或非常溫和的生物活性，能夠顯示細(xì)胞的滲透性，并且在長期口服的情況下能夠達(dá)到高血藥濃度。 有機小分子常見于：藥物化學(xué)，內(nèi)科醫(yī)師，配方科學(xué)（蓋侖制劑），藥劑學(xué)，藥理學(xué)等領(lǐng)域。 有機小分子不常見于 ：動物醫(yī)療，農(nóng)業(yè)科學(xué)，食物化學(xué)，營養(yǎng)學(xué)，化妝品，或其他等領(lǐng)域。 投標(biāo)截止時期2016年6月26日, 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/projectRoom/index?challenge=9933854 Seeking Safe Drug-like Small Organic Molecules for Human Use with Negligible Biological Effects TAGS: Chemistry, Life Sciences, Food/Agriculture, Royal Society of Chemistry, Ideation AWARD: $20,000 USD | DEADLINE: 6/26/16 | ACTIVE SOLVERS: 106 | POSTED: 4/27/16 Boehringer Ingelheim (The Seeker) is interested in small organic molecules that are safe for human use, show no, or very mild, biological activity, display cell permeability, and achieve high concentrations (μM) in the plasma when chronically administered via the oral route. This is an Ideation Challenge with a guaranteed award for at least one submitted solution. Source: InnoCentive Challenge ID: 9933854 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive Ideation Challenge-Specific Agreement Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Ideation Challenge only. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. If you click \\"I agree\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\"CSA\\") will be a valid and binding agreement between you and InnoCentive and in addition to the existing Terms of Use for all purposes relating to this InnoCentive Challenge. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply. 1. Proposed Solutions. As a Solver you may submit to InnoCentive your idea (your \\"Proposed Solution\\") to the InnoCentive Ideation Challenge to which this CSA relates (\\"InnoCentive Challenge?\\"). InnoCentive will make reasonable efforts to transmit Proposed Solutions to Seekers, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution on an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning your Proposed Solution to InnoCentive or the Seeker, if requested. 2. Acceptance of Proposed Solution and License to Use.InnoCentive will notify you within a commercially reasonable period of time after the end of the Time Period set forth in the Challenge Statement whether your Proposed Solution has been selected by Seeker for an Award. The Seeker will judge all Proposed Solutions against the guidelines set out in the Challenge Statement and determine, in its sole discretion, which Proposed Solution best addresses the Challenge Statement guidelines. The Seeker has absolute and sole discretion to determine whether to accept your Proposed Solution, or any Proposed Solution, and whether to make an Award, or multiple Awards. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\'s failure to win an award. The meeting of the Challenge Statement guidelines does not automatically mean that the Proposed Solution will be eligible for an Award. Proposed Solutions must NOT contain or include ideas, concepts, solutions or technology in respect of which a third party owns or controls the intellectual property. Proposed Solutions and descriptions thereof may not include trademarks or trade names of corporations or entities without the permission of their owners. By entering, you represent and warrant that: ? your entire Proposed Solution is an original work by you and you have not included third-party content (such as writing, text, graphics, artwork, logos, photographs, dialogue from plays, likeness of any third party, musical recordings, clips of videos, television programs or motion pictures) in or in connection with your Proposed Solution, unless (a) otherwise requested by the Seeker and/or disclosed by you in your Proposed Solution, and (b) you have either obtained the rights to use such third-party content or the content of the Proposed Solution is considered in the public domain without any limitations on use; ? no person or entity other than you has any right, title or interest in any part of your Proposed Solution; ? unless otherwise disclosed in the Proposed Solution, the use thereof by Seeker, or the exercise by Seeker of any of the rights granted by you under this Agreement, does not and will not infringe or violate any rights of any third party or entity, including, without limitation patent, copyright, trademark, trade secret, defamation, privacy, publicity, false light, misappropriation, intentional or negligent infliction of emotional distress, confidentiality, or any contractual or other rights; ? you have all the rights, licenses, permissions and consents necessary to submit the Proposed Solution and to grant all of the rights that you have granted to Seeker hereunder, including the right for Seeker to use and develop derivative works of and from the Proposed Solution; ? all persons who were engaged by you to work on the Proposed Solution or who appear in the Proposed Solution in any manner have: a. given you their express written consent to submit the Proposed Solution for unlimited, royalty-free use, exhibition and other exploitation in any manner and in any and all media, whether now existing or hereafter discovered, throughout the world, in perpetuity; b. provided written permission to include their name, image or pictures in or with your Proposed Solution (or if a minor who is not your child, you must have the permission of their parent or legal guardian) and you may be asked by Seeker to provide permission in writing; c. no claims for payment of any kind, including, without limitation, for royalties or residuals, has no approval or consultation rights or any rights of participation arising out of any use, exhibition or other exploitation of the Proposed Solution; and d. not been and are not currently under any union or guild agreement that results in any ongoing obligations resulting from the use, exhibition or other exploitation of the Proposed Solution; and ? you understand, recognize and accept that Seeker has access to, may create or has created materials and ideas which may be similar or identical to the Proposed Solution in concept, theme, idea, format or other respects. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\'s use of such materials. In the event that your entry is identical or similar to the Proposed Solution of another Solver, Seeker reserves the right, at the sole discretion of the Seeker, to either score one Proposed Solution higher than the other subject to the Challenge Statement guidelines or to randomly choose a Proposed Solution from all of those submitted which respond to the Challenge Statement guidelines. By entering, you agree that: (i) all Proposed Solutions become Seeker\'s property and will not be returned; (ii) Seeker (and its authorized representatives) have the unlimited right to alter and/or edit the Proposed Solution or any part or element thereof; and (iii) Seeker and its licensees, successors and assigns have the right to use any and all Proposed Solutions, and the names, likenesses, voices and images of all persons appearing in the Proposed Solution, for future advertising, promotion and publicity in any manner and in any medium now known or hereafter devised throughout the world in perpetuity. All intellectual property rights, if any, in the idea or concept demonstrated by the Proposed Solution will remain with the Solver. By submitting a Proposed Solution to this Challenge, each Solver agrees to grant to the Seeker a royalty free, non-exclusive license in respect of all such intellectual property rights, if any, for the purposes of commercial exploitation of the idea or concept demonstrated by the Proposed Solution. Notwithstanding granting the Seeker a perpetual, non-exclusive license for the PROPOSED SOLUTION, The Solver retains ownership of the PROPOSED SOLUTION. Please also be aware that your Proposed Solution may not be acknowledged and will not be received or held \\"in confidence\\" and your Proposed Solution does not create a confidential relationship or obligation of secrecy between you and any of the entities involved in this Challenge. 3. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an \\"Award\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of Awards, a \\"Revised Award Amount\\", if applicable) shall be paid to you by InnoCentive within thirty (30) days after occurrence of each of the following: 1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of Award payment from the Seeker. Payment of any Award is conditioned upon your cooperation with InnoCentive\'s verification procedures. The Award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any Award, or any part of any Award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the Award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on Awards shall be your sole responsibility. 4. GENERAL CONDITIONS. Seeker has the right to verify each Solver\'s eligibility and compliance with this CSA. The Seeker is a third-party beneficiary of this CSA, with the right to enforce the terms and conditions hereof directly against you. Participation is conditioned on providing the data required on the online registration form. Personal data will be processed in accordance with InnoCentive\'s Privacy Policy which can be located athttp://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. Solvers should not register with multiple e-mail and/or street addresses. In the event of a dispute as to any Proposed Solution, the authorized account holder of the email address used to enter will be deemed to be the person who submitted the Proposed Solution. The authorized \\"account holder\\" is the natural person assigned an email address by an Internet access provider, online service provider or other organization responsible for assigning email addresses for the domain associated with the submitted address. 5. Representations and Warranties. You represent and warrant that: ? All information provided by you regarding yourself and, if applicable, your business (\\"Solver Information\\") is true, accurate, current, and complete information and you will maintain and update the Solver Information to keep it true, accurate, current and complete. ? If you are an individual representing a business or other entity, you are authorized to enter into this Agreement on behalf of that business or entity. ? Unless otherwise disclosed in the Proposed Solution, you are the owner of the Proposed Solution and the Proposed Solution does not infringe or violate any patent, copyright, trade secret, trademark or other third-party intellectual property right. ? You have the right to grant the license in the Proposed Solution as required by Section 2 of this CSA. 6. Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls.

碳酸氫鈉是預(yù)防初期牙齦炎的一種活性成分，它存在各種牙膏中。當(dāng)碳酸氫鈉高濃度存在于牙膏中，非常咸的味道會令人不愉快。 懸賞任務(wù)是，在高濃度碳酸氫鈉牙膏中，尋找一種掩蓋咸味道的技術(shù)。 懸賞截止時期2016年7月31日, 投標(biāo)網(wǎng)址：https://www.innocentive.com/ar/projectRoom/index?challenge=9933826 Masking Salty Taste TAGS: Royal Society of Chemistry, Chemistry, Food/Agriculture, Life Sciences, RTP AWARD: See details | DEADLINE: 7/31/16 | ACTIVE SOLVERS: 94 | POSTED: 5/05/16 Sodium bicarbonate is a salt that is used as an ingredient in various products for many applications across various industries. It has a particularly strong salty taste, hence in applications where it is ingested, the salty flavour is pronounced. That is the case in toothpastes, where the beneficial gum protection effect that sodium bicarbonate delivers is overshadowed by the unpleasant salty taste that is felt by consumers, making such toothpastes unpopular. Do you have a technology that can mask the salty taste and make it imperceptible in toothpastes? This is a Reduction-to-Practice Challenge that requires written documentation, experimental proof-of-concept data, and, if requested by the Seeker, sample delivery. Source: InnoCentive Challenge ID: 9933826 Sign Agreement For This Challenge By electronically signing the agreement below, you are indicating your intention to view the details of this specific InnoCentive Challenge. Viewing the Challenge Details does not obligate you to perform any work on this challenge. Print this Agreement for your records InnoCentive RTP Challenge-Specific Agreement Please Read This Carefully! You and InnoCentive are agreeing to a Challenge-Specific Solver Agreement for this particular InnoCentive Challenge only, as permitted in the Terms of Use. The Seeker for this InnoCentive Challenge has required that you accept these special terms, so please take the time to understand them. If you click \\"I agree\\" and proceed to the Project Room for this InnoCentive Challenge, this Challenge-Specific Agreement (\\"CSA\\") will be a valid and binding agreement for all purposes relating to this InnoCentive Challenge and in addition to your agreement to abide by the Terms of Use when you registered as a Solver. Please print and keep a copy of this CSA. No provisions you may have agreed to that are specific to any other individual InnoCentive Challenge will apply. 1. Your Responsibility to Avoid Obstacles. InnoCentive needs to know that if you solve the InnoCentive Challenge there will not be any legal obstacles to completing the sale of your rights to InnoCentive, which is the only way that you can receive the Award. You agree to be responsible for avoiding obstacles to transferring all Intellectual Property and Work Product (altogether, the \\"Solution IP\\") if you submit a Proposed Solution chosen as a winning Solution.You will not receive an Award if you cannot transfer the Solution IP. 2. Your Guarantee. You agree that if and when the time comes to transfer the Solution IP, you will give a guarantee (the \\"Guarantee\\") that the transfer is lawful in exchange for the one-time payment of the Award to you alone, and that no consents, approvals or contracts that you did not already have before starting the InnoCentive Challenge are necessary from or with anyone else, such as: a. Your employer; b. Any former employer or other entity you are or have been associated with or have a contract with regarding Intellectual Property you develop; c. Anyone collaborating with you on the development of the Solution IP; d. Anyone else whose Intellectual Property you use or incorporate in the Solution IP; e. Any government official, regulatory body or other authority (for example, if any of the Solution IP is within the scope of a technology export control law in your country prohibiting its transfer to InnoCentive in the United States, or if the required assignments or licenses of the Solution IP are otherwise subject to public registration, review and/or approval) f. The holder of any lien (for example, if a bank or other creditor has obtained a mortgage or security interest in any of the Solution IP); g. Anyone who may be entitled to royalties or other payments relating to any of the Solution IP either by law or contract. 3. Your Obligations to Protect Potential Solution IP. In order to be eligible for an Award, during the period from when you begin work on the InnoCentive Challenge until the expiration of the Time Period as set forth in the Challenge Statement, you shall not: a. Grant away any rights in the Work Product or Proposed Solution you are developing (\\"Potential Solution IP\\"), or do anything else that would prevent you from granting the Option for the Exclusivity Period; b. Reveal to any third party, except on terms of strict confidentiality, any information that relates to Potential Solution IP or do anything else likely to impair any of the Potential Solution IP; or c. Do anything that would cause the failure of your Guarantee. 4. Exclusivity Period. By submitting your Proposed Solution you agree to grant to InnoCentive and the Seeker the following rights, for a period of 180 days (the \\"Exclusivity Period\\") from the deadline set forth in the InnoCentive Challenge Statement (the \\"Deadline\\"): (a) an exclusive option to acquire exclusive rights to the Proposed Solution for use in connection with the InnoCentive Challenge (the \\"Option\\"), as described in this Agreement, and (b) a non-exclusive, worldwide license to use, copy, distribute and create derivative works of the Work Product for purposes of review, analysis and testing the Proposed Solution, (collectively, these nonexclusive rights and the Option are referred to as the \\"Exclusive Option Rights\\"). InnoCentive will make reasonable efforts to transmit relevant Proposed Solutions to Seekers, however, nothing herein shall be construed as requiring InnoCentive to transmit every Proposed Solution submitted in response to an InnoCentive Challenge to a Seeker. In addition, by submitting your Proposed Solution you thereby agree to provide reasonable assistance and additional information concerning Work Product and your Proposed Solution to InnoCentive or the Seeker during the Exclusivity Period, if requested. By granting the Exclusive Option Rights you agree that during the Exclusivity Period (and thereafter, if the Option is exercised), you are prohibited from (x) using, the Proposed Solution or the Work Product or (y) disclosing to or granting or assigning or transferring any rights to a third party to use the Proposed Solution or the Work Product for any purpose, including the application for patents or similar intellectual property rights. 5. Validation of Winners. Once the Shortlist of Proposed Solutions has been selected, additional due diligence checks will take place prior to any final Awards being issued. These may include (but are not limited to) completion of a conflict of interest questionnaire, anti-bribery, anti-corruption, human rights screening, and checks to ensure the information provided in the application is genuine. The Seeker is only able to grant the Awards if all the criteria and due diligence checks are completed satisfactorily in the opinion of the Seeker. 6. Acceptance of Proposed Solution and Transfer of Intellectual Property. InnoCentive will notify you within a commercially reasonable period of time after the Deadline and before the termination of the Exclusivity Period whether a Seeker accepts your Proposed Solution and wishes to exercise an Option (\\"Acceptance\\"). For purposes of this Agreement, \\"Acceptance\\" shall mean the selection of your Proposed Solution by the Seeker as meeting the Solution Acceptance Criteria as set forth in the InnoCentive Challenge Statement. The Seeker has absolute and sole discretion to determine whether to Accept your Proposed Solution, or any Proposed Solution, and whether to make an Award, multiple Awards or any Award. Solver acknowledges and agrees that InnoCentive is not responsible for and has no liability for selection of a winning solver, if any. Solver further agrees to hold InnoCentive legally harmless in regard to selection of a winning solver, if any. Solver agrees to hold InnoCentive legally harmless for any advice it may provide as to the quality or suitability of submitted solutions and agrees to waive any claim against InnoCentive for Solver\'s failure to win an award. The meeting of the Solution Acceptance Criteria does not mean that the Proposed Solution will be Accepted by a Seeker. In the event that your Proposed Solution is not Accepted within the Exclusivity Period, the Exclusive Option Rights will terminate without further notice to you. Upon Acceptance of your Proposed Solution by a Seeker and payment of an Award to you (see \\"Payments\\"), you hereby assign and convey to InnoCentive all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, and you retain no rights to the Proposed Solution or the Work Product insofar as they are related to the InnoCentive Challenge. In the event that the Work Product cannot be assigned and conveyed under statutory law, you herewith grant to InnoCentive a worldwide, unlimited, perpetual, irrevocable, and exclusive license to use, make, have made, market, copy, modify, lease, sell, distribute, and create derivative works of the Work Product, including the right to assign the foregoing license to Seekers (all such rights collectively referred to as \\"Intellectual Property\\") . If you utilize any processes in development of the Work Product which are the subject of patent rights owned by you, you agree to grant to InnoCentive a worldwide, non-exclusive, perpetual, royalty-free right and license to practice any patented processes used in the Work Product, including the right to assign the foregoing license to Seekers. Furthermore, you agree that you will, during the term of this Agreement and at any time thereafter, execute all papers and do all things deemed necessary by InnoCentive or a Seeker to ensure that InnoCentive and the Seeker acquires all rights, title, and interests in and to the Proposed Solution and any Work Product that are related to the InnoCentive Challenge, including the rights to all Intellectual Property embodied therein, and that ensures that all such rights are transferred to Seeker. Such cooperation and execution shall be performed without additional compensation to you; provided, however, InnoCentive shall reimburse you for reasonable out-of-pocket expenses incurred at the specific request of InnoCentive. Upon payment of the Award, or termination of the Exclusive Option Rights for any reason, there will be no further obligations between you and InnoCentive or the Seeker with respect to the Proposed Solution, the Work Product, or the InnoCentive Challenge, except for the limitations on use and disclosure described under \\"Confidentiality\\", below. 7. Payments. If a Seeker Accepts your Proposed Solution, the payment amount (called an \\"Award\\") specified in the InnoCentive Challenge posted on the Service by a Seeker (or, in the case of partial payments of Awards, a \\"Revised Award Amount\\", if applicable) shall be paid to you by InnoCentive within thirty(30) days after occurrence of each of the following: 1) you are notified by lnnoCentive of your Proposed Solution’s Acceptance, and 2) the completion of certain verification procedures by InnoCentive, and review and acceptance of such results by Seeker, and 3) InnoCentive’s receipt of Award payment from the Seeker. Payment of any Award is conditioned upon your cooperation with InnoCentive\'s verification procedures and due diligence checks conducted by Seeker under clause 5. The Award will be paid to you locally, in U.S. Dollars, or if required by your local law, in your local currency equivalent based on the foreign exchange rate in effect on the date of the disbursement by InnoCentive. InnoCentive is not responsible for payment of any Award, or any part of any Award, to any party other than to the Solver through whom the Proposed Solution was submitted to the Service. You understand that the Award represents a complete payment, net of any local taxes that InnoCentive may be required to withhold, for any Accepted Proposed Solution and that you are not entitled to any other compensation of any kind. If local law does not require withholding of taxes, all taxes on Awards shall be your sole responsibility. 8. Escrows. The transfers of Solution IP and the Award or any Revised Award Amount (as determined by Seeker) will be in escrow as follows: a. Your transfer of the Solution IP will be to InnoCentive as escrow agent for the Seeker. The Solution IP will be released from this escrow and transferred to the Seeker upon the occurrence of (a) the completion of InnoCentive\'s verification of you; (b) the Seeker\'s payment of the Award to InnoCentive; and (c) the Seeker\'s payment of any other fees of InnoCentive pursuant to the separate agreement between Seeker and InnoCentive. b. The Seeker\'s payment of the Award will be to InnoCentive as escrow agent for you. The Award will be released from this escrow and transferred to you as soon as payment is due to you. 9. Confidentiality. During the term of this Agreement and at all times thereafter, you shall not disclose to any third party nor use for any purpose other than for the performance of this Agreement, any Confidential Information (as defined below) without the express written consent of the owner of the Confidential Information. These confidentiality obligations shall not apply to Confidential Information which: (a) is in the public domain, or which was publicly known or available on the date you originally accepted this Agreement (\\"Effective Date\\"); or (b) after the Effective Date becomes available to the public in a manner not involving a breach of any duty under this Agreement. Nothing herein shall preclude the ultimate disclosure of any information required by law. \\"Confidential Information\\" includes: ? All information set forth in the password protected areas of the Service (\\"Service Information\\"), (the presentation of Service Information via the Service shall not be deemed to be a public disclosure for purposes of this Agreement and shall not operate as an exclusion from Confidential Information); and ? During any Exclusivity Period and after Acceptance and exercise of an Option relating to a InnoCentive Challenge, any Work Product or Proposed Solution relating to said InnoCentive Challenge. The same restrictions on disclosure and use of Confidential Information described in this Section shall apply to the use or disclosure by InnoCentive and Seekers of any Work Product or Proposed Solution during the Exclusivity Period and, if the Proposed Solution is not accepted, thereafter, unless the Proposed Solution or Work Product can be shown by business records of Seeker or InnoCentive to (1) have been known to them previously; (2) is independently created by personnel of Seeker or InnoCentive who had no access to the Proposed Solution or the Work Product; or (3) is subject to the exceptions to Confidentiality in (a) or (b) of this section; provided, however, notwithstanding the foregoing, nothing in this Solver Agreement shall prevent a Seeker from utilizing a winning Solution, for which an Award has been paid, to the extent that a winning Solution and any rejected Proposed Solution contain overlapping Work Product. Notwithstanding anything herein to the contrary, you recognize that other persons may have provided Seeker or others, or made public, or may in the future submit, or make public, materials that are the same or similar to your Proposed Solution. You acknowledge and agree that Seeker shall have the right to use such same or similar materials, and that you will not be entitled to any compensation arising from Seeker\'s use of such materials. 10. Disclosure of Transfers of Value a. Seeker has made an ongoing commitment to transparency in its dealings with healthcare professionals and healthcare organisations worldwide; b. Seeker is required to publicly disclose transfers of value it makes to healthcare professionals and healthcare organisations under the European Federation of Pharmaceutical Industries and Associations Code on disclosures of transfer of value from pharmaceutical companies to healthcare professionals and healthcare organisations (“EFPIA Code”); c. A transfer of value for these purpose means the Award payment, and any expenses that may be incurred in connection with the grant of the Award which Seeker reimburses to you. d. The payments to be made by Seeker under this engagement are transfers of value that Seeker is required to publicly disclose under the EFPIA Code; e. Your name and contact details (other than email address) will be included in reports that Seeker will publish on publicly accessible websites, along with details of the transfers of value made, to meet Seeker’s transparency reporting obligations; f. Disclosures will be made on the basis of the most recent information Seeker has received from you. g. Seeker will publish details of all transfers of value made to you from 1 January 2016. Reports will be published annually on a publicly accessible website or another platform, such as a central platform provided by EFPIA and this publication will be maintained for at least 3 years. h. Prior to publication/disclosure, Seeker will provide you with a statement of the transfers of value it proposes to disclose against your name; i. You acknowledge and agree that these disclosures will be made. 11. ETHICAL STANDARDS AND HUMAN RIGHTS Unless otherwise required or prohibited by law, you warrant, to the best of your knowledge, that in relation to the Proposed Solution: ? you do not employ engage or otherwise use any child labour in circumstances such that the tasks performed by any such child labour could reasonably be foreseen to cause either physical or emotional impairment to the development of such child; ? you do not use forced labour in any form (prison, indentured, bonded or otherwise) and your employees are not required to lodge papers or deposits on starting work; ? you provide a safe and healthy workplace, presenting no immediate hazards to your employees. Any housing provided by you to your employees is safe for habitation. You provide access to clean water, food, and emergency healthcare to your employees in the event of accidents or incidents at your workplace; ? you do not discriminate against any employees on any ground (including race, religion, disability or gender); ? you do not engage in or support the use of corporal punishment, mental, physical, sexual or verbal abuse and do not use cruel or abusive disciplinary practices in the workplace; ? you pay each employee at least the minimum wage, or a fair representation of the prevailing industry wage, (whichever is the higher) and provide each employee with all legally mandated benefits; ? you comply with the laws on working hours and employment rights in the countries in which you operate; ? you are respectful of your employees’ right to join and form independent trade unions and freedom of association. You agree that you are responsible for controlling your own supply chain and that you shall encourage compliance with ethical standards and human rights by any subsequent supplier of goods and services that are used by you when performing your obligations in relation to the Proposed Solution. You shall ensure that you have ethical and human rights policies and an appropriate complaints procedure to deal with any breaches of such policies. Seeker reserves the right upon reasonable notice (unless inspection is for cause, in which case no notice shall be necessary) to enter your premises to monitor your compliance of the warranties set out above and you shall, subject to compliance with law, furnish Seeker with any relevant documents requested by Seeker in relation thereto. 12. COMPLIANCE WITH LAWS AND ANTI-CORRUPTION ? You shall comply fully at all times with all applicable laws and regulations, including but not limited to applicable anti-corruption laws, of the territory in which you conduct business with Seeker. ? Where, in the course of working on the Proposed Solution, you will interact with third parties (other than your own sub-contractors) or will interact in any way with healthcare professionals or government officials (as defined in Annex 1), you hereby give the warranties and representations set out in, and shall comply with, the provisions of Annex 1. ? Seeker shall be entitled to terminate your participation in a Challenge immediately if you fail to perform your obligations in accordance with this Clause and, where applicable, Annex 1. You shall have no claim against Seeker for compensation for any loss of whatever nature by virtue of the termination of your participation in the Challenge in accordance with this Schedule. To the extent (and only to the extent) that the laws of the territory provide for any such compensation to be paid to you upon the termination of your participation, you hereby expressly agree to waive (to the extent possible under the laws of the territory) or to repay to Seeker any such compensation or indemnity. 13 APPLICATION TO INDIVIDUALS. For the avoidance of doubt, Clauses 11 and 12 above apply to both individuals as well as companies. 14. General Conditions: InnoCentive and/or Seeker has the right to verify each Solver\'s eligibility and compliance with this CSA, and to eliminate any Solver, or terminate any Solver\'s registration on the basis of its investigation. Participation is conditioned on providing the data required on the online registration form. Personal data will be processed in accordance with InnoCentive\'s Privacy Policy which can be located athttp://www.innocentive.com/privacy.php. Solvers should direct any request to access, update, or correct information to InnoCentive. Neither InnoCentive nor Seeker is responsible for human error, theft, destruction, or damage to Proposed Solutions, or other factors beyond its reasonable control. Seeker reserves the immediate right to disqualify any Solver who, in InnoCentive\'s sole discretion: (i) is not in compliance with the Terms of Use or this CSA, (ii) tampers with the submission process, the Challenge, or the Website; or (iii) is acting in an uncooperative, unsportsmanlike, disruptive, abusive, or threatening manner. 15. Third Party Beneficiary. You and InnoCentive acknowledge and agree that any Seeker shall be a third- party beneficiary of this Agreement, and each shall have the right to assert and enforce the provisions of this Agreement directly on its own behalf. 16. Conflict. In the case of any conflict between the terms of this CSA and the Terms of Use, this CSA controls. # # # Annex 1 ANTI BRIBERY AND CORRUPTION REQUIREMENTS 1. You represent that you have not been convicted of or pleaded guilty to a criminal offence, including one involving fraud, corruption, or moral turpitude, that you are not now, to the best of your knowledge, the subject of any government investigation for such offenses, and that you are not now listed by any government agency as debarred, suspended, proposed for suspension or debarment, or otherwise ineligible for government programs. 2. You represent and warrant that, except as disclosed in writing: (1) you do not have any interest which directly or indirectly conflicts with your proper and ethical performance of activites in relation to participation in the Challenge and (2) you shall maintain arms length relations with all third parties (including government officials) with which you deal for or on behalf of Seeker, or in the performance of activities in relation to participation in the Challenge. 3. Seeker shall have the right to conduct an investigation and audit of your business to monitor compliance with the terms of this Annex. You shall cooperate fully with such investigation or audit, the scope, method, nature and duration of which shall be at the sole reasonable discretion of Seeker. 4. You shall ensure that all transactions in relation to participation in the Challenge are properly and accurately recorded in all material respects on your books and records and each document upon which entries such books and records are based is complete and accurate in all material respects. You must maintain a system of internal accounting controls reasonably designed to ensure that you maintain no off-the-books accounts. 5. You agree that Seeker may make full disclosure of information relating to a possible violation of these terms at any time and for any reason to any competent government bodies and its agencies, and to whomsoever Seeker determines in good faith has a legitimate need to know. PREVENTION OF CORRUPTION – THIRD PARTY GUIDELINES Seeker’s Anti-Bribery and Corruption Policy requires compliance with the highest ethical standards and all anti-corruption laws applicable in the countries in which Seeker (whether through a third party or otherwise) conducts business. The policy requires all Seeker employees and any third party acting for or on behalf of Seeker to ensure that all dealings with third parties, both in the private and government sectors, are carried out in compliance with all relevant laws and regulations and with the standards of integrity required for all Seeker business. Seeker values integrity and transparency and has zero tolerance for corrupt activities of any kind, whether committed by Seeker employees, officers, or third-parties acting for or on behalf of the Seeker. Corrupt Payments – Seeker employees and any third party acting for or on behalf of Seeker, shall not, directly or indirectly, promise, authorise, ratify or offer to make or make any “payments” of “anything of value” (as defined in the glossary section) to any individual (or at the request of any individual) including a “government official” (as defined in the glossary section) for the improper purpose of influencing or inducing or as a reward for any act, omission or decision to secure an improper advantage or to improperly assist the company in obtaining or retaining business. Government Officials – Although Seeker′s policy prohibits payments by Seeker or third parties acting for or on its behalf to any individual, private or public, as a “quid pro quo” for business, due to the existence of specific anticorruption laws in the countries where we operate, this policy is particularly applicable to “payments” of “anything of value” (as defined in the glossary section), or at the request of, “government officials” (as defined in the glossary section). Facilitating Payments – For the avoidance of doubt, facilitating payments (otherwise known as “greasing payments” and defined as payments to an individual to secure or expedite the performance of a routine government action by government officials) are no exception to the general rule and therefore prohibited. You shall not contact, or otherwise meet with any Government Official with respect to any transactions required in relation to participation in the Challenge, without the prior written approval of Seeker and, when requested by Seeker, only in the presence of a Seeker designated representative. GLOSSARY The terms defined herein should be construed broadly to give effect to the letter and spirit of the ABAC Policy. Seeker is committed to the highest ethical standards of business dealings and any acts that create the appearance of promising, offering, giving or authorising payments prohibited by this policy will not be tolerated. Anything of Value: this term includes cash or cash equivalents, gifts, services, employment offers, loans, travel expenses, entertainment, political contributions, charitable donations, subsidies, per diem payments, sponsorships, honoraria or provision of any other asset, even if nominal in value. Payments: this term refers to and includes any direct or indirect offers to pay, promises to pay, authorisations of or payments of anything of value. Government Official shall mean: ? Any officer or employee of a government or any department, agency or instrument of a government; ? Any person acting in an official capacity for or on behalf of a government or any department, agency, or instrument of a government; ? Any officer or employee of a company or business owned in whole or part by a government; ? Any officer or employee of a public international organisation such as the World Bank or United Nations; ? Any officer or employee of a political party or any person acting in an official capacity on behalf of a political party; and/or ? Any candidate for political office